An event imagined by
AIS BIOTECH
AIS Biotech aims to offer a new therapeutic alternative for the prevention and treatment of infectious diseases.
By developing a new class of biotherapies—sugar-based anti-infective decoys—we seek to combat existing and emerging infections as well as antibiotic resistance.
Thanks to an eco-friendly sugar bioproduction platform technology, AIS Biotech produces biopharmaceuticals capable of deceiving pathogens by mimicking their natural targets.
Our first drug candidate, GlycoFlu, targets influenza, a major public health concern.
Space
Pavillon Région Auvergne-Rhône-Alpes
